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Abstract
Both mouse and human embryonic stem cells can be differentiated in vitro to produce a variety of somatic cell types. Using
a new developmental tracing approach, we show that these cells are subject to massive aberrant CpG island de novo
methylation that is exacerbated by differentiation in vitro. Bioinformatics analysis indicates that there are two distinct forms
of abnormal de novo methylation, global as opposed to targeted, and in each case the resulting pattern is determined by
molecular rules correlated with local pre-existing histone modification profiles. Since much of the abnormal methylation
generated in vitro appears to be stably maintained, this modification may inhibit normal differentiation and could
predispose to cancer if cells are used for replacement therapy. Excess CpG island methylation is also observed in normal
placenta, suggesting that this process may be governed by an inherent program.
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Introduction
Both mouse and human embryonic stem cells can be derived
from early pre-implantation embryos and grown indefinitely in
culture. These cells maintain their pluripotency as indicated by the
observation at least in mouse that they can generate a full
organism [1], and both human and mouse ES cells can be
differentiated in vitro to a large variety of different cell types [2,3].
These studies suggest that embryonic stem cells harbor an
epigenetic profile similar to that of the embryo itself and that
this pattern has within it the plasticity to generate differentiated
cell types.
One of the major epigenetic marks of the genome is DNA
methylation. In the early pre-implantation embryo, DNA methyl
groups derived from the gametes are largely erased and a new
bimodal pattern is re-established in every individual at about the
time of implantation [4,5]. This basal pattern is generated by a
wave of indiscriminate de novo methylation in conjunction with a
mechanism for protecting CpG island-like sequences on the basis
of local cis acting elements [6,7]. Following this step, differentiated
cells lose the ability to carry out global de novo methylation [8],
but the basic pattern is none-the-less maintained through every
cell division by Dnmt1, which recognizes hemimethylated sites
generated at the replication fork [9]. As development proceeds,
each individual cell type can then undergo additional de novo
methylation [10,11] or demethylation [4] events in a gene-specific
manner.
Although mouse embryonic stem cells are derived from the
ICM, genome-wide analysis indicates that, unlike the blastocyst,
they are methylated in a manner similar to somatic cells,
suggesting that from the epigenetic standpoint, they actually
behave like cells at the time of implantation [4]. This observation
is substantiated by the fact that ES cells retain the ability to carry
out global de novo methylation and are capable of distinguishing
and protecting CpG islands from this process [6,7]. The same is
probably true of human ES cells, as well. Upon differentiation in
vitro, ES cells appear to undergo appropriate changes in DNA
methylation, as indicated, for example, by the well-documented de
novo methylation that takes place on pluripotency genes, such as
Oct-3/4 and Nanog [12]. Nonetheless, several studies indicate
that differentiation in vitro may also be accompanied by aberrant
de novo methylation at CpG islands [13]. Since this type of
modification is thought to be irreversible in the post-implantation
embryo in vivo, it is likely that these abnormal events could
adversely affect the quality of differentiated tissues derived from
ES cells in culture.
In order to study this problem, we used developmental
principles to generate a new approach for assessing what should
be considered a normal methylation pattern in ES cells. On the
basis of this in vivo perspective, we found that both mouse and
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human ES cells growing in vitro have aberrant DNA methylation
that could have physiological effects on their ability to undergo
proper differentiation.
Materials and Methods
Differentiation of ES cells
Mouse endoderm and mesoderm were differentiated from ES-
GscgfpSox17huCD25 cells originally derived from line EB5 by
sequence targeting [14]. Briefly, ES cells were plated on collagen-
coated culture dishes and differentiated in a serum-free culture
medium with 10 ng/ml human Activin A. Cells were collected
after 6 days and subjected to FAC sorting to obtain definitive
endoderm (Gsc+Sox17+ECD+) or mesoderm (Gsc+Sox172ECD2).
Embryoid bodies (EBs) were formed from ES cells (TT2) [15]
diluted and grown in medium without LIF by the hanging drop
method. After 2 days, aggregates were pooled and cultured in
suspension for 4 additional days in bacterial Petri-dishes. Mouse
teratomas were generated by resuspension of ES cells (D3,C4) into
PBS-Basement membrane matrix (1/1) and subcutaneous injec-
tion into NOD-SCID mice. Animals were sacrificed 2 weeks after
injection. ES cells (J1) [16] were treated with 1 mM retinoic acid
(RA) for 8 days [17] in order to induce a neuro-ectodermal
population.
Human ES cells (CSES2) [18] were grown on feeder layer and
induced to EBs as described previously [19]. Briefly, cells were
transferred using trypsin/EDTA to plastic Petri dishes to allow
their aggregation and prevent adherence to the plate. In order to
induce neuro-ectodermal differentiation, 1 mM RA was added to
monolayer ES cells grown on gelatin-coated plates and cells were
harvested after 10 days. Undifferentiated human ES cells (I6, H13)
[10] were sorted using the SSEA3 marker prior to mDIP analysis.
mDIP microarrays
Human fetal (20–25 weeks) DNA samples were purchased from
Biochain. All mouse DNAs were extracted from C57Bl/6 and
mDIP was performed as described previously [10]. Human (10 mg)
or mouse (40 mg) genomic DNA was sonicated to an average
fragment size of 300–1000 bp, precipitated with 400 mM NaCl, 2
volumes of ethanol and 1 ml glycogen. 1.5 mg were set aside as the
Input fraction. DNA was denatured and anti-5-methylcytidine
monoclonal antibody (10 ml for 5 mg) [20,21] was added and
incubated on a rotator at 4uC overnight. 40 ml Dynabeads (Sheep
anti-Mouse IgG) were prewashed with 0.1% BSA/PBS and added
to the DNA. The DNA was then washed 3 times and Ab-bound
DNA resuspended and extracted with proteinase K, phenol-
chloroform and ethanol precipitation. Purified DNA was checked
for enrichment (Bound/Input) using Real time PCR on specific
gene regions known to be methylated.
The Input and Bound DNAs were labeled and hybridized on
mouse (105 K) or human (244 K) CpG island microarrays (Agilent
Technologies, http://www.genomics.agilent.com) as described
previously [10]. We used feature extraction software (Agilent) to
obtain background-subtracted intensity values for the two fluores-
cence dyes on each individual array feature and for carrying out
linear normalization and calculation of the log ratio (Cy5/Cy3).
Data was analyzed as previously described [10]. Briefly, probe log
ratio signals were transformed into Z-scores according to their Tm
and an Island Methylation Score (IMS) was then calculated by
averaging the island corresponding probes’ Z-scores. Data for both
mouse (GSE54664) and human (GSE24270) analyses can be
accessed from the GEO-NCBI database repository.
Data analysis
Previous published work on undifferentiated and differentiated
ES cells and in vitro differentiation was analyzed by downloading
data from the appropriate GEO datasets. We used genomic
bisulfite data (GSE11034) for mouse DNA [5,13]. Methylation
percent was calculated for every CpG that had a minimum of 5
reads and these were then aligned in order to generate an average
methylation value for each CpG island (as defined by UCSC).
Islands with data for less than three CpGs were not included.
H3K27 tri-methylation (GSE12241) from mouse ES cells [22].
The average density score per CpG island was calculated with
background taken as the average score for all CpG islands. Whole-
genome human DNA methylation was downloaded from the
roadmap epigenomics project (http://www.roadmapepigenomics.
org/) as determined by Reduced representation bisulfite sequenc-
ing (RRBS).
Previous published work on de-novo methylation in cancer was
analyzed by downloading data from The Cancer Genome Atlas
(TCGA - https://tcga-data.nci.nih.gov/tcga/) and average meth-
ylation values were calculated for every CpG island. Human
ChIP-seq data for H3K27 and H3K4 tri-methylation was
obtained from the NIH Roadmap Epigenomics Mapping Con-
sortium. We compared 200 CpG islands deemed abnormally
methylated in serum-grown ES cells and found them to be about
10% more methylated than the levels seen when cultured in 2i
conditions using previously published data (GSE42929) [29].
Statistical analysis
The significance (P value) of difference between background-
island DNA methylation patterns in somatic tissues as opposed to
differentiated and undifferentiated ES cells was determined by a
two-tailed, non-paired, equal-variance T-test. The significance of
H3K27me3 enrichment on target CpG islands as well as
comparison between CpG island sets was calculated using the
hypergeometric test [23,24].
Bisulfite analysis
Single island reads were obtained by Bisulfite conversion of
genomic DNA that was carried out using the EZ DNA
Methylation-Direct Kit (Zymo Research) according to the
manufacturer’s instructions. PCR primers were designed using
Methyl Primer ExpressH Software v1.0 (https://www2.
appliedbiosystems.com). Barcodes and adaptors were added to
the primers and deep-sequenced using the Ion Torrent (Life
Technologies).
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of the Hebrew University (NIH approval number:
OPRR-A01-5011).
Results
Mouse ES cells were grown in culture and induced to
differentiate using a variety of commonly-employed strategies
(Materials and Methods). Embryoid bodies were formed by
aggregation. We treated cells with retinoic acid to induce a
neuro-ectodermal population and also purified definitive endo-
derm or mesoderm from monolayer cultures exposed to Activin
induction [25]. DNA was then isolated and subjected to mDIP
microarray analysis which measures the average methylation level
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of all CpG moieties in every island of the genome [10], and the
results analysed by comparison to DNA samples from a large
panel of normal adult tissues.
We identified about 9,500 CpG islands constitutively unmethy-
lated in every cell type (Materials and Methods). This pattern
reflects events that occur at the time of implantation when the
entire genome becomes de novo methylated while almost all CpG
islands are protected. This basic bimodal profile represents a
‘‘ground state’’ which is then maintained during every cell division
throughout development [26]. Strikingly, hundreds of these CpG
islands were found to be highly modified (Z-score.0.75) in ES
cells differentiated in vitro (Fig. 1). Since most of these islands do
not appear to be substantially methylated anywhere in the
organism (Z-score,0), it is likely that this in-vitro modification
represents some form of artifact that does not reflect the normal
epigenetic status at these early stages of embryogenesis. Further
support for this idea was obtained by carrying out mDIP on DNA
from early mouse embryos (8.5–12.5 dpc) and by comparing to
data from near-implantation embryos (Fig. S1a in File S1) which
show that the real in vivo level of methylation at these target CpG
islands is indeed very low.
This phenomenon of aberrant methylation is not unique to the
specific differentiation experiments carried out in our laboratory.
Using partial genome-wide bisulfite sequencing, it has already
been shown that ES cells differentiated in vitro to neural
precursors (NPCs) undergo de novo methylation (.80%) at over
300 CpG island promoters, even though almost all of these same
sequences were completely unmethylated in corresponding neural
embryonic cells representing this same approximate stage of
development [13]. In order to validate this finding using our
developmental approach, we carried out additional bioinformatics
analysis on this same database. We were able to discern over
2,000 CpG islands aberrantly methylated (average.50%) follow-
ing differentiation and thousands of additional sequences show
methylation levels significantly higher than their normal values in
a variety of somatic cell types (Fig. S1a in File S1), generating a
pattern very similar to that determined by mDIP analysis (P,
102132) (Materials and Methods).
Since the excess modification observed in differentiated ES cells
was originally detected in comparison to normal tissue DNA, we
next examined the methylation state of these same CpG islands in
undifferentiated mouse ES cells. While the same target sequences
appear to be relatively unmethylated in these undifferentiated
cells, surprisingly, they were found to be much more methylated
than the normal population of CpG islands in the cell (Fig. S1b &
S1c in File S1), and there is some evidence that this may increase
as a function of time in culture [13,27,28]. It is unlikely that this
excess methylation is representative of the implantation embryo in
vivo. Indeed, these target sites were actually found to be
unmethylated in DNA from 6.5 and 7.5 d embryos (Fig. S1a in
File S1). It should be noted that by growing ES cells in 2i medium,
it is possible to lower DNA methylation to levels similar to those
seen at the ICM stage [29,30,31], and in this way remove most of
the excess CpG island methylation (Materials and Methods). It is
unlikely, however, that these ground-state cells would generate
differentiated derivatives with normal methylation (see [31]) since
they would still be required to pass through a more advanced ES
cell state prior to differentiation in vitro.
Figure 1. Excess methylation in differentiated mouse ES cells. DNA from normal mouse tissues, undifferentiated and differentiated ES cells,
post implantation embryos and teratomas were subject to mDIP microarray analysis. Heat map of 1,000 CpG islands methylated (IMS.0.75) in at
least one of the ES cell types out of 9,500 CpG islands constitutively unmethylated (IMS,0) in all tissue samples (see Materials and Methods). A
number of different ES cell lines were used in this study. Embryoid bodies and retinoic acid treated cells were derived from TT2, while endoderm and
mesoderm were derived from EB5. An estimate [10] for the average percent of methylation in fetal tissues as compared to in vitro differentiated cells
is also shown.
doi:10.1371/journal.pone.0096090.g001
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We next asked whether aberrant de novo methylation also
occurs in human ES cells. To this end, we used mDIP to analyze
CpG island methylation patterns in a number of different
undifferentiated ES cell lines and in cell cultures induced to
differentiate by several alternative techniques. Once again, the
data was compared to normal DNA extracted from human
embryo tissues. As noted previously [10], the human genome has
about 13,000 constitutively unmethylated CpG islands, and
differentiated ES cells demonstrated strong methylation in almost
1,000 of these sequences (Fig. 2). We then analyzed published
methylation data on human ES cells that was obtained using high
resolution RRBS (www.roadmapepigenomics.org), exclusively
focusing on CpG islands that are unmethylated in a wide range
of different tissue cell types. Here too, differentiated ES cells were
found to have a large number of aberrantly methylated sequences
similar to those identified by mDIP analysis (P,102124) and the
same was true for induced pluripotent stem (iPS) cells, as well (Fig.
S2 in File S1).
As is the case with mouse ES cells, the methylation targets
detected in differentiated cells were found to be modified in several
human ES cell lines even prior to differentiation, with the level of
modification being quite high, and in some cases very similar to
that seen in differentiated cells derived from the same lines (Fig. 2).
This over-modification was observed even though the human ES
cells used for this analysis were actually pre-sorted specifically to
select for the undifferentiated phenotype (Materials and Methods).
Furthermore, by examining published data from other laborato-
ries, it appears that this same phenomenon is typical of many other
human ES cell lines, as well (Fig. S2 in File S1).
It should be noted that while several previous studies identified
aberrant de novo methylation during mouse [13,32] or human
[28] ES-cell differentiation in vitro, the normal-tissue tracing
strategy that we have introduced in order to understand these
events from a developmental perspective, has revealed a much
larger range of abnormally methylated CpG islands. This is
especially true for the DNA modification seen in undifferentiated
human ES cells which lack a normal tissue control and would
never have been detected without having the benefit of the
developmentally-projected pattern derived from somatic tissues.
Taken together, our studies indicate, for the first time, that the
generation of excess methylation in culture represents an intrinsic
process that actually begins in undifferentiated ES cells and may
then be exacerbated by a wide variety of in vitro differentiation
techniques.
During normal development, almost all post-implantation de
novo methylation takes place in a site-specific manner, with a high
preference for polycomb target sites [10]. In keeping with this, our
studies show that over 70% of the excess methylated sites
associated with in vitro differentiated mouse ES cells are also
marked with above-background levels of H3K27me3 (P,102159)
in the parent line. Furthermore, we have observed that the degree
of methylation following differentiation is linearly proportional to
the underlying pre-set local concentration of this histone
modification in undifferentiated ES cells as determined from
several different studies (Fig. 3a & b). This suggests that the
polycomb system may play a role in this targeting process and this
is consistent with the finding that Ezh2, a member of the polycomb
complex, is actually capable of directly recruiting DNA methyl
transferases [33,34].
While de novo methylation may indeed be directed by
polycomb marking in undifferentiated cells, once it occurs, the
presence of methyl groups appears to bring about a dramatic
reduction in H3K27me3 levels at these same sites as measured in
the resulting differentiated cells (Fig. S3 in File S1). This reciprocal
effect between DNA and histone modification has also been noted
for the de novo methylation that occurs in cancer [35,36]. It thus
appears that during in vitro differentiation many sites of polycomb
repression are getting replaced with more permanent DNA
methylation silencing, thus, perhaps, limiting regulatory plasticity.
The primary bimodal methylation pattern of the genome is
formed in vivo at the time of implantation by a combination of
global de novo methylation together with CpG island protection,
and ES cells represent a good model for this process. Although
these unmethylated windows are ultimately dictated by underlying
sequence information, ChIP analysis in ES cells indicates that the
presence of H3K4me3 may take part in this protection, since this
modification is associated with every unmethylated island and is
almost completely absent from those regions that undergo de novo
methylation [10]. In order to test whether H3K4me3 may also
play a role in modulating the abnormal de novo methylation that
takes place during ES-cell differentiation in vitro, we next analyzed
the degree of this modification as a function of H3K4 methylation
(Fig. 3c). These results clearly show that while sites of polycomb
are all targets for this reaction, the co-presence of high-level
H3K4me3 at these same CpG islands appears to have a
concentration-dependent protective effect.
In general, there appear to be two modes of de novo
methylation in vivo, global as opposed to targeted [4]. While
Figure 2. Excess methylation in human ES cells. DNA from normal
human fetal tissues, undifferentiated and in vitro differentiated ES cells
were subject to mDIP microarray analysis. Heat map shows 950 CpG
islands methylated (IMS.0.75) in at least one of the differentiated ES
cell types out of 13,000 CpG islands constitutively unmethylated (IMS,
0) in fetal tissue samples. Retinoic acid treated cells and embryoid
bodies were derived from CSES2. An estimate [10] for the average
percent methylation in fetal tissues as compared to in vitro
differentiated cells is also shown.
doi:10.1371/journal.pone.0096090.g002
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aberrant methylation in mouse ES cells is correlated with
polycomb targeting (Fig. 3), this does not seem to be true of the
abnormal methylation observed in human ES cells, which shows
only a marginal enrichment for CpG islands that bind the
polycomb complex (Fig. S4a in File S1). One possibility is that in
these cells, excess modification comes about by a distortion of the
implantation-specific global DNA methylation that operates
constitutively in dividing ES cells. As previously noted, this global
process brings about non-specific methylation of the entire
genome, while sparing CpG islands, and this protection has been
shown to be highly correlated with the level of H3K4me3 in local
nucleosomes [10].
In order to determine whether this underlying process may be
disrupted in human ES cells, we further analyzed histone
modification patterns of the aberrantly methylated CpG islands.
Despite the lack of enrichment for polycomb, these islands are
characterized by a preferentially low spectrum of H3K4me3, both
as measured in ES cells themselves as well as other tissues (Fig. S4b
in File S1). Previous studies have shown that it is possible to derive
an accurate algorithm for predicting which DNA sequences are
protected from de novo methylation at the time of implantation
[10]. Strikingly, our analysis indicates that the same sites
abnormally modified in human ES cells are characterized by a
relatively low algorithm score for their potential to remain
unmethylated (Fig. S4a in File S1). Taken together, these results
are consistent with the idea that these sites are indeed the least
capable of being protected from global methylation.
It is well known that ES cells grown in culture can fully
contribute to normal development when incorporated into
blastocysts and transplanted into pseudo-pregnant females. In
light of the findings that these cells have abnormal methylation
patterns to begin with, we next asked whether this modification
actually persists during normal development. To this end, we took
advantage of an ES cell line that expresses GFP, generated
chimeric embryos by blastocyst injection and then separated out
the labelled somatic cells from 17.5 dpc embryos using FACS. In
the original ES cell line, we were able to detect heavy abnormal
methylation in many sample CpG islands. In contrast, the in vivo-
derived tissues from labelled cells were completely lacking this
mark at all of the tested CpG islands and thus had a pattern similar
to normal embryonic DNA (Fig. 4).
This experiment suggests that during normal development early
embryonic cells have an inherent ability to remove aberrantly
modified sequences. This process could be carried out by a CpG
island-specific demethylation pathway similar to that which occurs
at select loci in the ICM at the time of implantation [5] and which
has been previously identified in ES cells [7,37,38]. Alternatively,
it may come about because the early embryonic environment
induces global demethylation [5], thereby clearing the slate prior
to the de novo methylation which would ensue upon implantation.
A similar phenomenon is observed when ES cells undergo
differentiation during the formation of teratomas in vivo. In this
case as well, sites abnormally modified in tissue culture underwent
partial demethylation when placed in an in vivo setting (Fig. 1). It
should be noted that cell selection could also operate to reset
aberrant levels of DNA methylation accrued by prolonged culture.
Even though the de novo methylation that takes place in vitro
appears to be aberrant in terms of normal development, one is
struck by the fact that this process is clearly programmed at the
level of protein–DNA interactions. It thus appears that the logic
and apparatus used to carry out this targeted methylation is built
into the genome. For this reason, we asked whether there may be
instances where this same form of modification actually occurs in
vivo. Since this was not observed in normal embryos or somatic
tissues, we next examined extraembryonic tissues, such as
placenta. Strikingly, mouse placenta at both 14.5 and 19.5 dpc
was found to have modified CpG islands with a high percentage
(80%) of them representing polycomb targets (P,102229) (Fig. S5
in File S1), as has been noted previously [39]. Similar results were
Figure 3. De novo methylation is proportional to H3K27me3
concentration. a. IMS (Fig. 1) of all 9,500 constitutively unmethylated
CpG islands in undifferentiated, endoderm-differentiated ES cells and
adult tissue DNA graphed as a function of H3K27me3 density [22]. Each
point represents the average IMS within a 5 unit span. b. Average
methylation levels of all constitutively unmethylated CpG islands in
endoderm (IMS), NPCs (%) and adult tissue (%) were graphed against
H3K27me3 density partitioned into ten bins. The X-axis also shows
average H3K27me3 levels in each percentile. c. Methylation levels in
adult tissue, ES differentiated into endoderm and NPCs of all
constitutively unmethylated CpG islands with above background
concentrations (.2) of H3K27me3 graphed against their H3K4me3
density in ES.
doi:10.1371/journal.pone.0096090.g003
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obtained in human placenta, as well. These experiments suggest
that CpG island methylation of the type seen in differentiated cells
in culture actually mimics a process of modification that takes
place during normal extraembryonic development in vivo.
Discussion
By means of a tracing method that uses data from adult and
fetal tissues to determine the CpG island methylation pattern of
early embryonic cells, we have been able to define a common
baseline for DNA methylation. With this as a standard for the first
stages of methylation at the time of implantation, we have found
that both mouse and human embryonic stem cell lines carry an
aberrant pattern of excess methylation that is made worse by a
variety of in vitro differentiation strategies. This effect clearly
represents an artifact of growing cells in culture, firstly, because
levels of CpG island methylation in normal differentiated tissues
are much lower, and because abnormal modification does not
occur when ES cells are grown into teratomas or introduced into
the normal blastocyst, thereby undergoing differentiation in an in
vivo setting. It is not known whether these defects in methylation
represent an intrinsic aspect of growth in culture per se, or whether
it may be possible to create conditions in vitro that might prevent
the appearance of this phenomenon.
Any attempt to understand the molecular mechanism of
abnormal methylation must take into consideration the parameters
that control methyl group metabolism in ES cells. Even though
mouse ES cells are initially derived from the ICM at a stage where
most methyl groups are erased from the genome [5], they appear
to have a fully developed bimodal pattern of methylation whereby
most of the genome is highly methylated, with CpG islands
remaining unmodified. This suggests that from the point of view of
methylation, these in vitro cells behave as if they are actually at a
slightly more advanced stage of development, one that perhaps
mimics the early implantation embryo. In keeping with this, it has
been shown that these cells actively de novo methylate newly-
introduced DNA and also have the capacity to protect CpG island
sequences from this process [6,7]. These properties are probably
unique to embryonic stem cells, as it has been shown both in vivo
and in vitro that DNA inserted into somatic cells does not
generally become de novo methylated [8,40].
During the very early stages of post-implantation development
in vivo, pluripotent cells lose their ability to constantly set up and
reset global DNA methylation, but the basic overall pattern
initially formed by this process is retained through all subsequent
cell divisions by a semi-conservative maintenance mechanism [4].
Although it is not known exactly when this transition actually
occurs, it is clear that it must involve downregulation of de novo
methylation activity [41] as well as a shift from global to locus-
specific recruitment [17]. In addition, differentiation may bring
about changes in the protective ability of specific CpG island
sequences. Our studies suggest that the growth of ES cells and
their differentiation in vitro may upset this delicate balance, and as
a result we observe aberrant methylation on CpG islands that are
normally preserved in an unmethylated form in vivo. This
overmethylation appears to take place on two different levels,
global and locus-specific.
The dominant de novo methylation in mouse ES cells is
directed to CpG islands that are targets for polycomb. It has been
known for a long time that differentiated somatic cells grown for
extended periods of time in tissue culture also acquire an aberrant
methylation pattern [42]. To emphasize this point, we used our
tracing approach to analyze the methylation patterns of long-
standing immortalized a and b pancreatic islet cell lines and this
revealed over 1,200 aberrantly methylated regions as compared to
normal b cells purified directly from fresh pancreatic tissue (P,
10296) (Fig. S6 in File S1). Here too, over 80% of the methylated
sites appear to be polycomb targets, and the same is true for the
hypermethylation observed in cancer [43,44,45]. Our studies in
ES cells clearly show that the degree of abnormal methylation is
linearly dependent on the concentration of H3K27me3 present at
these loci prior to differentiation (Fig. 3), and it is thus very likely
that this repression complex, itself, actually mediates the
biochemical recruitment of Dnmts to these sites [33,34].
It appears that in vivo, the levels of recruited de novo
methylases are very low [45], and as a result, almost all polycomb
targets remain relatively unmethylated, showing only a slow
increase as a function of aging [46,47,48]. However, under stress
conditions in culture or during tumorigenesis, there may be
Figure 4. Resetting de novo methylation in vivo. Blastocysts
injected with ES cells carrying a GFP expression vector were
transplanted into pseudo-pregnant mice. Whole embryos were isolated
at 16 dpc and sorted for GFP+ and GFP2 cells. DNA from these cells was
then treated with bisulfite and deep-sequenced (Ion Torrent) at four
different specific CpG island sequences. a. 7,000 individual molecules of
island A containing nine individual CpGs with yellow indicating
methylation. b. Graph showing percent methylation for islands A, B, C
and D.
doi:10.1371/journal.pone.0096090.g004
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increased cellular levels of Dnmt3a and 3b [49,50] that would then
lead to the appearance of abnormal methylation. Undifferentiated
mouse ES cells in culture which mimic the implantation stage of
development, contain high levels of non-targeted Dnmt3a/3b
[41]. It is possible that differentiation in vitro brings about
abnormal changes in the distribution of these enzymes, thus
causing polycomb targets to undergo aberrant modification.
In human ES cells, a great deal of abnormal methylation is
already apparent in the undifferentiated state, and bioinformatics
analysis indicates that this does not preferentially occur at
polycomb targets. Rather, we observe de novo methylation over
a wide range of CpG islands, with preference for sequences having
a borderline inherent ability to be protected from this process.
This suggests that the aberrant modification observed in human
ES cells comes about through a distortion in the general process of
global methylation. In vivo, general de novo methylation
presumably takes place over a very short window of time. In
contrast, cells growing in culture are constantly exposed to the
methylation machinery over many generations, and this may bring
about an imbalance in the quantitative relationship between the
level of de novo methylation and the factors involved in keeping
CpG islands unmodified, thereby bringing about a shift in the
threshold for protection.
This could take place preferentially in human ES cells because
they are regarded as more comparable to mouse Epi stem cells, a
developmentally more advanced cell population [51]. It should be
noted that this abnormal modification would not have been
detected without comparison to the pattern determined by the
developmental tracing strategy adopted in our laboratory.
Furthermore, studies comparing somatic cell-derived iPS to
embryo-derived ES cells [52] are also flawed in this regard, failing
to take into consideration the possibility that the pattern in ES cells
may be abnormal to begin with (Fig. S2 in File S1). Despite
differences in the abnormal methylation observed in mouse vs.
human ES ells, it should be noted that the patterns themselves are
generated by a common mechanism that involves protection by
H3K4me3 regardless of the source of de novo methylation.
We have documented a considerable number of CpG islands
that get abnormally methylated in mouse ES cells, and a very large
percentage of these are located at promoters of genes involved in
differentiation or development (Table S1 in File S1). It is thus very
likely that this modification has profound effects on both cell
function and developmental plasticity. The precise influence of
abnormal DNA methylation is difficult to evaluate due to the lack
of expression profiles for equivalent normal cells in vivo. In
general, however, almost all of the genes that undergo de novo
methylation during the differentiation of mouse ES cells have low
expression levels in the undifferentiated cells [13,53], and this is
consistent with the idea that a large percentage of these sites, while
not DNA methylated, have bivalent promoters that are repressed
by the polycomb complex. These same genes, however, represent
important components required for differentiation, and if they
become methylated in culture, this could strongly affect the cells’
ability to activate them as part of the normal process of
development.
In addition to the developmental problems that may be caused
by DNA methylation, it should be noted that there could also be a
safety concern when using human ES cells that will ultimately be
transplanted back into patients. Indeed, our analysis indicates that
a large percentage of the excess-methylated sites in human ES cells
have been found to be hypermethylated in a variety of different
tumors (Fig. S7 in File S1). Since these modifications are most
likely irreversible in somatic cells, this could readily predispose
them to carcinogenesis. Thus, these results should serve as a
warning for using current approaches to generate in-vitro
differentiated cells for replacement therapy. Our molecular studies
will hopefully pave the way towards deciphering the mechanism of
this abnormal process and finding strategies for correcting it.
Abnormal hypo- and hyper-methylation of CpG islands is
observed in a wide variety of tumors, in somatic cells grown in
culture and following differentiation of embryonic stem cells in
vitro [54]. In most of these cases it has been shown that de novo
modification is specifically directed to polycomb targets. This
suggests the existence of an inherent process that is programmed at
the genome level, and raises the possibility that this type of
targeted de novo methylation may also occur during normal
development in vivo. In this paper, we demonstrate that a similar
epigenetic pathway is indeed associated with de novo methylation
in both mouse and human placenta [39,55,56,57]. Previous studies
already showed that extraembryonic tissues also undergo gener-
alized hypo-methylation [58]. While its role has not yet been
elucidated, it is very likely that this modification program has some
influence on placental physiology. A similar type of de novo
methylation also accumulates in many cell types during the normal
process of aging [46,47,48]. In this sense, the abnormal
modification seen in tissue culture, while triggered by local
environmental conditions, may actually be mediated by an
inherent regulatory program.
Supporting Information
File S1 Supporting Information. Figure S1. Bisulfite
methylation analysis of mouse ES cells. a. Heat map of RRBS
methylation data for normal mouse tissues, undifferentiated and
differentiated ES cells (NPC) and implantation embryos showing
the top 2,000 CpG islands found modified (.25%) in NPCs. It
should be noted that 70% of the aberrantly-methylated CpG
islands detailed in Fig. 1 overlap with the set shown here. b.
Methylation distribution in undifferentiated ES cells for 9,500
constitutively unmethylated (gray) CpG islands and the
2,000 CpG islands shown in a that were found to be methylated
in NPCs (blue). c. Methylation distribution (IMS, derived from
Fig. 1) in undifferentiated ES cells for the 9,500 constitutively
unmethylated CpG islands (gray) as opposed to the 1,000 CpG
islands (green) methylated following in vitro differentiation to
endoderm. Figure S2. DNA methylation in human ES cells. Heat
map analysis of CpG islands in human ES cells and normal tissues
as determined by RRBS (Road map). Group A includes CpG
islands that are abnormally methylated (.60%) in at least one
undifferentiated or differentiated ES cell type but constitutively
unmethylated (,20%) in all normal adult and embryo tissues.
Group B includes CpG islands that are methylated in a single
tissue type but unmethylated in others. For both groups, the same
CpG islands appear to be methylated in iPS cells, as well. Figure
S3. Scatter plot of H3K27me3 density in NPCs vs. undifferen-
tiated mouse ES cells for 9,500 CpG islands (see Fig. S1). The
2,000 aberrantly methylated islands (marked in red) show a
dramatic reduction in H3K27me3 density when ES cells are
converted to NPCs (a). H3K27me3 density in mouse brain is
shown for comparison (b). Figure S4. Markers of de novo
methylation. a. Table showing the percentage of abnormally-
methylated CpG islands that are marked with polycomb
(H3K27me3.2) and their average algorithm score (A2) both in
human and mouse ES cells. IMS data are from Figs. 1 and 2 and
methylation sequencing data are from Figs. S1 and S2. The
intrinsic ability of any CpG island to protect against de novo
methylation can be expressed as an algorithm that takes into
consideration underlying sequence features. Islands that are
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constitutively unmethylated have a high score (average of 2.0),
while methylated islands have a low score (21.80). Differentiated
mouse ES-cell methylation targets (Fig. 1) have, on average, an
intermediate score (0.8) that is significantly different (P,10263)
than the constitutively unmethylated CpG islands. b. Methylation
levels of all CpG islands as a function of local H3K4me3 density
for human ES cells before and after differentiation to endoderm.
The average levels in a collection of fetal tissues is shown for
comparison. Figure S5. DNA methylation in placenta. DNA
from normal mouse embryos and from placenta were subject to
mDIP microarray analysis. Heat map of 1,000 CpG islands
methylated in placenta out of 9,500 background CpG islands (see
Fig. 1). An estimate for the average percent methylation is also
shown. Figure S6. DNA methylation in mouse pancreatic a and
b cells. DNA from mouse pancreatic cell lines (TC and Min6) and
natural b cells purified form fresh pancreatic islets were subject to
mDIP microarray analysis. Out of 9,500 background CpG islands
(Fig. 1), IMS Heat map of 2,000 CpG islands deemed methylated
(IMS.0.75) in either the a or b cell lines as compared to DNA
from embryos (where none have a positive binary methylation
score). Only 5 are actually methylated in ex-vivo b cells. An
estimate for the average percent methylation is also shown. Ex-
vivo cells were obtained by preparing pancreatic islets from 2 to 8
month old transgenic mice carrying a Pdx1-GFP construct by
ductal perfusion with collagenase. Islets were then hand-picked
and dissociated to single cells with trypsin and subjected to FAC
sorting using Anti-insulin antibodies. Figure S7. Methylation
levels in cancer. Heat map of CpG islands deemed methylated in
human ES cells (Fig. 2) compared to methylation levels (P value) in
a number of different tumor samples from the Cancer Genome
Atlas as determined by Infinium Human Methylation 450 array
assay and methylation levels (%) in normal tissues as determined
by RRBS from the Roadmap Epigenomics Project (www.
roadmapepignenomics.org). The excess methylation seen in each
tumor type is significantly greater than that observed in normal
tissues (minimal P value,10280). Table S1. Genes involved in
differentiation and development that are associated with aber-
rantly methylated CpG islands.
(DOC)
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